Curated News
By: NewsRamp Editorial Staff
September 10, 2024

Therma Bright: Innovating in Healthcare Markets

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • Therma Bright Inc. aims to capitalize on a $1.62 billion DVT treatment market with its Venowave VW5 circulation booster.
  • The Venowave VW5 is an FDA-approved circulation booster that stimulates blood flow to prevent DVT and has various healthcare applications.
  • Therma Bright's innovative medical devices and diagnostic solutions, including the Venowave VW5, aim to improve health outcomes and prevent serious complications like pulmonary embolism.
  • Therma Bright is developing a Digital Cough Test app using AI to monitor respiratory diseases based on the sound of a person’s cough, along with other innovative products.

Impact - Why it Matters

This news matters because Therma Bright's innovative products and partnerships have the potential to significantly impact the healthcare industry, addressing unmet clinical needs and improving treatment options for conditions such as DVT, stroke, and respiratory diseases. Investors and individuals with these health concerns should keep an eye on Therma Bright's advancements.

Summary

Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making visible strides with its diverse portfolio of innovative medical devices and diagnostic solutions designed to address unmet clinical needs. The company's flagship product, the Venowave VW5, is aiming to capitalize on a deep vein thrombosis (DVT) treatment market expected to grow to $1.62 billion by 2032. Therma Bright has also secured a nationwide U.S. distribution partner for Venowave, and received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS).

Additionally, the company has invested in Inretio, the developer of the Preva® clot-retrieval device, positioning itself to take a share of the growing global coronary stents market. Therma Bright's stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and COPD, also holds promise in the multi-billion-dollar COPD market. The company's innovation pipeline includes various other products in development, making it a key player in multiple healthcare markets.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Therma Bright: Innovating in Healthcare Markets

blockchain registration record for the source press release.